Anti-ovarian Tumor Immune Responses Induced by the Fusion Protein of Anti-Idiotypic Single Chain Antibody-Heat Shock 70 in Vitro

刘春雨,崔恒,昌晓红,叶雪,付天云,程洪艳,张果,熊英,成夜霞,张丽,赵旸
DOI: https://doi.org/10.3969/j.issn.1672-1861.2008.04.012
2008-01-01
Abstract:Objective Anti-idiotypic single chain antibody 6B11ScFv can mimic OC166-9,the antigen of ovarian carcinoma in our previous research. This study is aimed to evaluate the immunogenesis of the fusion protein,6B11ScFv-mHSP70 in vitro; and to explore the probability of 6B11ScFv-mHSP70 as an ovarian cancer vaccine.Methods 6B11ScFv-mHSP70 was expressed by E.coli and the fusion protein was higher than 95% purity after denature and renaturation. The immune activity of 6B11ScFv-mHSP70 was analyzed with ELISA. Isolated female peripheral blood mononuclear cells (PBMC) expressing HLA-A2 were co-cultured and stimulated with 6B11ScFv-mHSP70. The proliferations of PBMC and cytotoxicity were examined by CCK-8 and LDH release test respectively. Phenotype of T lymphocyte stimulated by 6B11ScFv-mHSP70 was analyzed by immune flow cytometry.Results 6B11ScFv-mHSP70 showed capacity of binding to ovarian cancer monoclonal antibody COC166-9 and anti-mHSP70 antibody. It also could stimulate PBMC to proliferate and presented cytotoxicity to ovarian carcinoma cells expressing OC166-9 and HLA-A2. Compare to untreated cells,6B11ScFv-mHSP70 treated lymph cells showed phenotypes as significantly increased in CD4+ T cell,slightly increased in CD8+T cell,significantly increase in CD4+/CD8+ ratio and significantly decreased in (CD4+CD25+)/CD4+ ratio.Conclusions 6B11ScFv-mHSP70 can induce cellular immunity against ovarian carcinoma in vitro. This finding provides experimental evidence for clinical use of 6B11ScFv-mHSP70 as anti-idiotype vaccine against ovarian carcinoma.
What problem does this paper attempt to address?